Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Ga68-Dolacga Injection in Healthy Volunteers
NCT03908957Phase 1Completed
- Sponsor
- National Atomic Research Institute
- Start
- Feb 2019
- Primary completion
- Aug 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gallium ga 68 dotatate in liver disease, sponsored by National Atomic Research Institute. Primary endpoints: Clinically significant changes in serum biochemical, hematological, and urinalysis tests at 14 days, Clinically significant changes in blood pressure, heart rate, and body temperature at 14 days and 2 more. Started Feb 2019; status: completed.
02
Drugs
gallium ga 68 dotatate
03
Conditions
liver disease
Beyond the preview
Go deeper on NCT03908957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03908957.